<DOC>
	<DOCNO>NCT01247623</DOCNO>
	<brief_summary>Primary objective : Determination safety tolerability GV1001 administration combine Temozolomide ( base blood sample adverse event ) . Feasibility combine active immunisation Temozolomide treatment . Determination immunological response administration GV1001 Temozolomide measure presence DTH skin test reaction specific T-cell response . Secondary : Evaluation objective tumour response The trial exploratory study main objective estimate safety feasibility combine active immunisation chemotherapy . However , trial may also indicate efficacy combination .</brief_summary>
	<brief_title>Trial With Telomerase Peptide Vaccine In Combination With Temozolomide Patients With Advanced Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Histologically confirm diagnosis malignant melanoma . Previously untreated nonresectable disease Measurable evaluable tumour . Age ≥ 18 ≤ 75 year . Performance status ECOGWHO 0 , 1 2 ( Appendix III ) Written inform consent ( Appendix II ) Adequate bone marrow liver , heart renal function : WBC count &gt; 3.0 x 109/L platelet count &gt; 100 x 109/L . ASAT , ALAT &lt; 2 x upper normal laboratory value . Serum creatinine &lt; 2 x upper normal laboratory value . Previous treatment chemotherapy . Clinical sign brain metastasis . Severe cardiac insufficiency ( NYHA III IV ) uncontrolled and/or unstable cardiac coronary artery disease . Severe active infection HIV hepatitis B Hepatitis C. Medication severe intercurrent disease might affect immunocompetence ( e.g . immunosuppressant , systemic corticosteroid ) . Pregnancy , breastfeed absence adequate contraception fertile patient . Simultaneously participation clinical study . Any reason , opinion investigator , patient participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Non-resectable , advanced malignant melanoma .</keyword>
</DOC>